<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15024">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986608</url>
  </required_header>
  <id_info>
    <org_study_id>EP0036</org_study_id>
    <secondary_id>2012-003084-21</secondary_id>
    <nct_id>NCT01986608</nct_id>
  </id_info>
  <brief_title>Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects</brief_title>
  <official_title>A Single Center Open-label, Randomized, Single-dose, 3-way Crossover Study to Compare the Safety, Tolerability, and Pharmacokinetics of Lacosamide Administered as Oral Tablet or Intravenous Infusion in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to compare the pharmacokinetics of Lacosamide (LCM) following a
      single 30-minute or 60-minute iv infusion of LCM 200 mg with those following a single oral
      dose of LCM 200 mg in healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Maximum plasma concentration of Lacosamide (Cmax) after oral and intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The value of the maximum plasma concentration will be directly obtained from the observed plasma concentration versus time curves.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration of Lacosamide (AUC 0-t) after oral and intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero up to infinity (AUC) after oral and intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The area under the curve extrapolated to infinity is calculated as the sum of AUC(0-t) and a residual part extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach a maximum plasma concentration (tmax)  after oral and intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT) after oral and intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate constant of elimination (Î»z) after oral and intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) after oral and intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CL/F) after oral administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL) after intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) after oral administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz) after intravenous administration of Lacosamide</measure>
    <time_frame>Pharmacokinetic samples will be taken at predose/preinfusion, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose (start of infusion)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Lacosamide 30-minute iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 60-minute iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide oral tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide infusion</intervention_name>
    <description>Strength: 10 mg/mL for infusion
Form: solution for infusion
Dosage: 200 mg, single dose
Duration: 30-minute infusion or 60-minute infusion</description>
    <arm_group_label>Lacosamide 30-minute iv</arm_group_label>
    <arm_group_label>Lacosamide 60-minute iv</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide oral</intervention_name>
    <description>Strength: 200 mg
Form: film-coated tablet
Dosage: 200 mg, single dose
Duration: single oral intake</description>
    <arm_group_label>Lacosamide oral tablet</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male and female volunteers with the age between 20 and 55 years old

        Exclusion Criteria:

          -  Subject has participated or is participating in any other clinical studies of
             investigational drug or another investigational medical product within the last 3
             months

          -  Subject has a history (within 6 months) before screening visit of chronic alcohol
             and/or drug abuse and/or has smoked and/or has a history or presence of
             cardiovascular, respiratory, hepatic, renal, GI, endocrinological, or neurological
             disorders

          -  Subject has a history of suicide attempt or current active suicidal ideation

          -  Subject has experienced a myocardial infarction and/or made a blood donation or any
             other blood loss more than 400 ml in the last 3 months

          -  Subject is pregnant or nursing

          -  Subject is not healthy (eg, taking any drug treatments, having any medical or
             emotional/psychological problems, a drug/alcohol abuse, having abnormal safety
             parameters and/or was positive for  HIV, HBsAg, HCV)

          -  Subject has an excessive use of alcohol or/and cigarettes and/or caffeine and/or
             abnormal diet and/or has taken grapefruit or grapefruit drink within 7 days before
             intake of Investigational Medicinal Product (IMP)

          -  Subject has a clinically significant abnormality in the 12-lead Electrocardiogram
             (ECG)

          -  Subject is having clinically relevant drug hypersensitivity to any components of the
             investigational medicinal product
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>001</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <keyword>Vimpat</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Japanese</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
